Testing blood DNA changes in lung cancer on immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study checks whether tiny bits of tumor DNA in the blood can be measured over time in people with non-small cell lung cancer who are receiving immunotherapy. It aims to see if these blood tests can help track the cancer response or changes during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You agree to join after learning about the study and sign consent.
- You have non-small cell lung cancer that is stage IIIA, IIIB, or IV.
- Your daily functioning is good enough (WHO performance status 2 or less).
- You are being treated with immunotherapy, either one drug or a combination.
- Your care plan includes a measurable tumor target and you have PD-L1 test results available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This trial checks whether a device called TheraSure CNI-Monitor can be used while people with advanced lung cancer receive immunotherapy. It aims to improve monitoring during palliative (comfort-focused) treatment.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.